skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hinsveiflur og heilahimnubólur og hliðstæður - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
norditropin flexpro stungulyf, lausn 5/1,5 mg/ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 5/1,5 mg/ml
norditropin flexpro stungulyf, lausn 15/1,5 mg/ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 15/1,5 mg/ml
norditropin flexpro stungulyf, lausn 10/1,5 mg/ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 10/1,5 mg/ml
norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 5 mg /1,5 ml
norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg/1,5 ml
norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml
novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg/1,5 ml
saizen (saizen lq) stungulyf, lausn í rörlykju 5,83 mg/ml
merck ab - somatropinum inn - stungulyf, lausn í rörlykju - 5,83 mg/ml
saizen (saizen lq) stungulyf, lausn í rörlykju 8 mg/ml
merck ab - somatropinum inn - stungulyf, lausn í rörlykju - 8 mg/ml
genotropin stungulyfsstofn og leysir, lausn 12 mg
pfizer aps - somatropinum inn - stungulyfsstofn og leysir, lausn - 12 mg